Literature DB >> 18328946

Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas.

Camelia-Maria Monoranu1, Bei Huang, Inna Lukashova-V Zangen, Stefan Rutkowski, Giles Hamilton Vince, Nicolas U Gerber, Bernhard Puppe, Wolfgang Roggendorf.   

Abstract

Losses and rearrangements of genetic material on chromosome 6q are frequently found in several human malignancies, including primary central nervous system tumors. We previously used microsatellite analysis of ependymomas to identify frequent deletions in regions 6q15 approximately q16, 6q21 approximately q22.1, and 6q24.3 approximately q25.3. To refine our preliminary analysis of potential prognostic regions, we used a panel of 25 microsatellite markers located between 6q15 and 6qter in 49 pairs of matched normal and tumor specimens from 28 children and 21 adults with ependymoma. Allelic deletions were detected in 34 of 49 patients (69%), and two common regions of deletions (6q24.3 and 6q25.2 approximately q25.3) were identified. A short segment of approximately 0.4 Mb between D6S1612 and D6S363 on 6q25.3, containing the SNX9 and SYNJ2 genes, exhibited the highest number of aberrations (n = 38). Pediatric tumors showed slightly fewer aberrations (64%) than adult tumors (76%) and also predominantly exhibited small interstitial deletions, in contrast to the extensive losses of genetic material in adults. Pediatric anaplastic intracranial (supra- and infratentorial) ependymomas harboring the 6q25.3 deletion (n = 9) showed significantly longer overall survival than did patients of the same group without the aberration (n = 6), independent of the extent of resection (P = 0.013). This supports the identified deletion on 6q25.3 as a candidate favorable prognostic parameter and warrants further investigation.

Entities:  

Mesh:

Year:  2008        PMID: 18328946     DOI: 10.1016/j.cancergencyto.2007.12.008

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  14 in total

1.  Sorting nexin 9 (SNX9) regulates levels of the transmembrane ADAM9 at the cell surface.

Authors:  Kasper J Mygind; Theresa Störiko; Marie L Freiberg; Jacob Samsøe-Petersen; Jeanette Schwarz; Olav M Andersen; Marie Kveiborg
Journal:  J Biol Chem       Date:  2018-04-05       Impact factor: 5.157

Review 2.  Understanding Ependymoma Oncogenesis: an Update on Recent Molecular Advances and Current Perspectives.

Authors:  Kirti Gupta; Pravin Salunke
Journal:  Mol Neurobiol       Date:  2015-12-28       Impact factor: 5.590

3.  Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.

Authors:  Catherine Godfraind; Joanna M Kaczmarska; Mehmet Kocak; James Dalton; Karen D Wright; Robert A Sanford; Fredrick A Boop; Amar Gajjar; Thomas E Merchant; David W Ellison
Journal:  Acta Neuropathol       Date:  2012-04-21       Impact factor: 17.088

Review 4.  Treatment of pediatric brain tumors.

Authors:  Matthias Karajannis; Jeffrey C Allen; Elizabeth W Newcomb
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

5.  Identification of microRNAs as potential prognostic markers in ependymoma.

Authors:  Fabricio F Costa; Jared M Bischof; Elio F Vanin; Rishi R Lulla; Min Wang; Simone T Sredni; Veena Rajaram; Maria de Fátima Bonaldo; Deli Wang; Stewart Goldman; Tadanori Tomita; Marcelo B Soares
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

6.  Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.

Authors:  Lorena V Baroni; Lakshmikirupa Sundaresan; Ayala Heled; Hallie Coltin; Kristian W Pajtler; Tong Lin; Thomas E Merchant; Roger McLendon; Claudia Faria; Molly Buntine; Christine L White; Stefan M Pfister; Mark R Gilbert; Terri S Armstrong; Eric Bouffet; Sachin Kumar; Michael D Taylor; Kenneth D Aldape; David W Ellison; Nicholas G Gottardo; Marcel Kool; Andrey Korshunov; Jordan R Hansford; Vijay Ramaswamy
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

Review 7.  Molecular genetics of ependymoma.

Authors:  Yuan Yao; Stephen C Mack; Michael D Taylor
Journal:  Chin J Cancer       Date:  2011-10

Review 8.  The Similarities and Differences between Intracranial and Spinal Ependymomas : A Review from a Genetic Research Perspective.

Authors:  Chang-Hyun Lee; Chun Kee Chung; Jung Hun Ohn; Chi Heon Kim
Journal:  J Korean Neurosurg Soc       Date:  2016-02-29

9.  ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines.

Authors:  M Khursheed; J N Kolla; V Kotapalli; N Gupta; S Gowrishankar; S G Uppin; R A Sastry; S Koganti; C Sundaram; J R Pollack; M D Bashyam
Journal:  Br J Cancer       Date:  2013-05-09       Impact factor: 7.640

10.  Genomic characterization of ependymomas reveals 6q loss as the most common aberration.

Authors:  Thale Kristin Olsen; Ludmila Gorunova; Torstein R Meling; Francesca Micci; David Scheie; Bernt Due-Tønnessen; Sverre Heim; Petter Brandal
Journal:  Oncol Rep       Date:  2014-06-16       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.